These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1248 related items for PubMed ID: 33166553

  • 1. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM, Kelly SP, Mylavarapu Bs AL, Holland GN, Coleman AL, Yu F, Hsu Ms S, Lum F, Gordon LK.
    Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
    [Abstract] [Full Text] [Related]

  • 2. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T.
    JAMA Dermatol; 2020 Sep 01; 156(9):982-986. PubMed ID: 32667663
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
    Fortes BH, Liou H, Dalvin LA.
    Br J Ophthalmol; 2021 Sep 01; 105(9):1263-1271. PubMed ID: 32830124
    [Abstract] [Full Text] [Related]

  • 7. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC, Hassel JC, Heinzerling L, Loquai C, Thoms KM, Ugurel S, Zimmer L, Gutzmer R, committee on “Cutaneous Adverse Events“ of the German Working Group for Dermatological Oncology (Arbeitsgemeinschaft Dermatologische Onkologie, ADO).
    J Dtsch Dermatol Ges; 2020 Jun 01; 18(6):582-609. PubMed ID: 32489011
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
    Gao S, He Z, Zhu J, Liang D, Zhao W, Yang S, Jiang W, Qiu K, Yu X, Wu J.
    Pharmacoepidemiol Drug Saf; 2022 Nov 01; 31(11):1199-1205. PubMed ID: 35689298
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
    Ji HH, Tang XW, Dong Z, Song L, Jia YT.
    Clin Drug Investig; 2019 Mar 01; 39(3):319-330. PubMed ID: 30674039
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL, Kwok GGW, Tang V, Li BCW, Leung R, Chiu J, Ma KW, She WH, Tsang J, Lo CM, Cheung TT, Yau T.
    J Immunother Cancer; 2021 Feb 01; 9(2):. PubMed ID: 33563773
    [Abstract] [Full Text] [Related]

  • 14. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL, Wang DY, Hu JX, Tian RY, Wang W, Su Q, Li H, Wang YL.
    Ocul Immunol Inflamm; 2022 Aug 01; 30(6):1449-1459. PubMed ID: 33970759
    [Abstract] [Full Text] [Related]

  • 15. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB.
    JAMA Oncol; 2018 Dec 01; 4(12):1721-1728. PubMed ID: 30242316
    [Abstract] [Full Text] [Related]

  • 16. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
    Chanson N, Ramos-Casals M, Pundole X, Suijkerbuijk K, José de Barros E Silva M, Lidar M, Benesova K, Leipe J, Acar-Denizli N, Pradère P, Michot JM, Voisin AL, Suárez-Almazor ME, Radstake TRD, Fernandes Moça Trevisani V, Schulze-Koops H, Melin A, Robert C, Mariette X, Baughman RP, Lambotte O, ICIR, Coordination, Co-Convenors, Steering Committee, Research Fellows, Data Scientist.
    Eur J Cancer; 2021 Nov 01; 158():208-216. PubMed ID: 34452793
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P, Champiat S, Voisin AL, Baldini C, Massard C, Laghouati S, Marabelle A, Lambotte O, Michot JM.
    Eur J Cancer; 2021 Nov 01; 158():217-224. PubMed ID: 34627664
    [Abstract] [Full Text] [Related]

  • 19. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
    Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X.
    Ann Rheum Dis; 2017 Oct 01; 76(10):1747-1750. PubMed ID: 28600350
    [Abstract] [Full Text] [Related]

  • 20. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ, Weppler A, Bhave P, Allayous C, Patrinely JR, Ott P, Sandhu S, Haydon A, Lebbe C, Johnson DB, Long GV, Menzies AA, Carlino MS.
    J Immunother Cancer; 2021 May 01; 9(5):. PubMed ID: 33963010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.